>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

March 28, 2014

FDA Update on the Shortage of Normal Saline

Summary:

FDA Update on the Shortage of Normal Saline

March 18, 2014

FDA MedWatch - Merit Medical Systems, Custom Procedural Trays/Kits Containing 1 percent Lidocaine HCl Injection, 10mg/mL: Recall - Particulates Found in Hospira supplied Lidocaine

Summary:

Merit Medical Systems Custom Procedural Trays Kits Recall Particulates Found in Hospira Lidocaine

March 18, 2014

McKesson Technologies Anesthesia Care: Recall - Patient Case Data May Not Match Patient Data

Summary:

McKesson Technologies Anesthesia Care Recall Patient Case Data May Not Match Patient Data

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Congressional Report Details Regulatory Oversight of Compounding Pharmacies

Wednesday, October 31, 2012

This week, Congressman Edward J. Markey (D-Mass.) released a report, Compounding Pharmacies, Compounding Risk, which examines FDA and state Boards of Pharmacy regulation of compounding pharmacies.  According to the report, the FDA has attempted to rein in activities of compounding pharmacies by issuing warning letters, but the nature of regulatory oversight and gaps in legal authority have led to 23 deaths and at least 86 serious illnesses or injuries in 34 states (not including the most recent outbreak).  The report explained that state Boards of Pharmacy do not typically undertake enforcement actions that relate to the safety or scope of drugs made by compounding pharmacies.  In spite of this deficiency, "FDA’s efforts to assure the safety of compounding pharmacies have been challenged at every juncture by some members of the compounding pharmacy sector."  The report concluded:

This analysis makes clear that state regulators are not, or cannot, perform the same sort of safety-related oversight of compounding pharmacy practices that FDA has historically undertaken. But it is also clear that absent clear new statutory authority, FDA’s efforts will ultimately be constrained by gaps in regulatory authority and thwarted by an industry that has historically resisted a federal role for the oversight of its activities.

Read the report.

View the latest information on the fungal meningitis outbreak.

« Back to Washington Alerts